Clinical trial · Observational
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
Predicting Pathological Complete Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy With MR Radiomics Method
NCT03238885CI-TRIAL-00036929completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Rectal Cancer | Malignant Rectal Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pelvic MR examination | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- LARC-CRT
- description
- LARC patients who will receive neoadjuvant CRT before surgical resection.
- interventionNames
- Diagnostic Test: pelvic MR examination
Primary outcomes (1)
- measure
- Pathological complete response(pCR)
- timeFrame
- within one week after surgery
- description
- Pathological complete response was defined as the absence of viable tumor cells in the primary tumor and lymph nodes.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * pathologically proved rectal cancer * locally advanced rectal cancer (≥T3 or N+) * a distance less than 12cm between the lower edge of tumor and the anal margin * no evidence of distant metastases * no prior anti-cancer therapy before treatment * scheduled to receive preoperative CRT Exclusion Criteria: * history or concurrent of other malignancy * incomplete preoperative CRT * failed to receive surgery or unavailable pCR assessment * poor quality of MR images for measurement * patient quit
References
Publications (0)
Data not yet available
No reference posted for this study.